Novo Nordisk Provides Update On The Zeus Phase 3 Trial In People With ASCVD, CKD And Inflammation
Adverse Event Rates Similar; Higher Serious Infections With Ziltivekimab Outcome Of Zeus Will Not Impact Novo Nordisk eur S Previously Communicated Adjusted Operating Profit Outlook For 2026 Outcome Will Result In A Non-Cash Impairment Charge In Q3 2026 While Ziltivekimab Demonstrated Target Engagement And Inhibition Of Il-6 Pathway This Did Not Translate Into Macerisk Reduction Two Additional Trials Planned To Continue
Story updates
11:23:55 AM UTC
SquawkNews
Novo Nordisk Provides Update On The Zeus Phase 3 Trial In People With ASCVD, CKD And Inflammation
11:24:41 AM UTC
SquawkNews
Novo Nordisk Shares Down 10.5% After Update On Zeus Phase 3 Trial
11:34:42 AM UTC
SquawkNews
Novo Nordisk Shares Down 10.5% After Update On Zeus Phase 3 Trial
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.